Skip to main content

Table 2 Key baseline characteristics of patients initiating 1 L RCC treatment (2011–2015): drug class and administration route

From: Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database

Characteristic

TK/VEGF inhibitor

(n = 1752)

mTOR inhibitor

(n = 233)

Oral

(n = 1674)

IV

(n = 318)

n

%

n

%

n

%

n

%

Age at diagnosis, median (Q1–Q3), years

62 (56–70)

62 (56–71)

61 (56–69)

64 (57–76)

Male

1220

69.6

166

71.2

1176

70.3

215

67.6

Employment status

 Active

568

32.4

69

29.6

563

33.6

79

24.8

 Retiree

652

37.2

78

33.5

617

36.9

113

35.5

 Long-term disability

11

0.6

1

0.4

8

0.5

4

1.3

 Other/unknown

521

29.7

85

36.5

486

29.0

122

38.4

Region

 Northeast

327

18.7

33

14.2

303

18.1

57

17.9

 North Central

467

26.7

52

22.3

451

26.9

68

21.4

 South

645

36.8

104

44.6

622

37.2

131

41.2

 West

296

16.9

40

17.2

280

16.7

59

18.6

 Unknown

17

1.0

4

1.7

18

1.1

3

0.9

Metropolitan statistical area

 Urban

1424

81.3

195

83.7

1359

81.2

267

84.0

 Rural

328

18.7

38

16.3

315

18.8

51

16.0

Insurance plan type

 Comprehensive

313

17.9

45

19.3

288

17.2

70

22.0

 HMO

204

11.6

22

9.4

189

11.3

38

12.0

 POS

130

7.4

17

7.3

120

7.2

28

8.8

 PPO

926

52.9

125

53.7

896

53.5

158

49.7

 Other

179

10.2

24

10.3

181

10.8

24

7.6

Insurance type

 Commercial

1120

63.9

142

70.0

1100

65.7

169

53.1

 Medicare

632

36.1

91

39.1

574

34.3

149

46.9

Index year

 2011

350

20.0

78

33.5

341

20.4

88

27. 7

 2012

350

20.0

62

26.6

333

19.9

80

25.2

 2013

392

22.4

25

10.7

373

22.3

45

14.2

 2014

327

18.7

38

16.3

309

18.5

58

18.2

 2015

333

19.0

30

12.9

318

19.0

47

14.8

Mean DCCI score (Q1–Q3)

0.70 (0–1)

0.76 (0–1)

0.66 (0–1)

0.93 (0–1)

Comorbidities

 Diabetes

484

27.6

48

20.6

442

26.4

90

28.3

 CKD

346

19.8

54

23.2

317

18.9

84

26.4

 Liver disease

307

17.5

40

17.2

306

18.3

45

14.2

 COPD

217

12.4

33

14.2

212

12.7

39

12.3

 CHF

113

6.5

37

15.9

111

6.6

40

12.6

Secondary metastatic sites

 Lung

798

45.6

101

43.4

804

48.0

99

31.1

 Liver

181

10.3

39

16.7

186

11.1

34

10.7

 Brain

161

9.2

25

10.7

162

9.7

26

8.2

 Bone

469

26.8

85

36.5

479

28.6

76

23.9

 Others

696

39.7

100

42.9

704

42.1

97

30.5

Nephrectomy prior to treatment

 Any nephrectomy

395

22.6

47

20.2

390

23.3

53

16.7

 Cytoreductive nephrectomy

380

21.7

41

17.6

377

22.5

45

14.2

  1. Data are n and % unless otherwise indicated. CHF congestive heart failure, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, DCCI Deyo-Charlson Comorbidity Index, HMO health maintenance organization, POS point-of-service, PPO preferred provider organization, Q quartile